NCT05541549View on ClinicalTrials.gov

A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML

PHASE2UnknownINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2025

Conditions

Progressive Multifocal Leukoencephalopathy

Interventions

BIOLOGICAL

CE-VST01-JC

CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions

Sponsors

Lead Sponsor

Cellevolve Bio Inc

All Listed Sponsors

lead

Cellevolve Bio Inc

INDUSTRY